

End of Result Set

Generate Collection Print 1

L1: Entry 1 of 1

File: DWPI

May 2, 2002

DERWENT-ACC-NO: 2002-373930

DERWENT-WEEK: 200241

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Identifying agents for treatment or prevention of cytomegalovirus infection, comprises contacting test compound with cellular kinase and detecting change in cellular kinase activity

INVENTOR: BEVEC, D; HABENBERGER, P; SCHUBART, D; STEIN-GERLACH, M

PRIORITY-DATA: 2000US-240750P (October 16, 2000)

PATENT-FAMILY:

PUB-NO

PUB-DATE

LANGUAGE

PAGES

MAIN-IPC

EP 1201765 A2

May 2, 2002

049

C12Q001/48

INT-CL (IPC): $\underline{A61}$ \underline{K} $\underline{39/395}$; $\underline{A61}$ \underline{K} $\underline{48/00}$; $\underline{A61}$ \underline{P} $\underline{31/12}$; $\underline{C07}$ \underline{K} $\underline{16/00}$; $\underline{C12}$ \underline{Q} $\underline{1/48}$; $\underline{C12}$ \underline{Q} 1/68

ABSTRACTED-PUB-NO: EP 1201765A

BASIC-ABSTRACT:

NOVELTY - Identifying compounds (A) for treating and/or preventing cytomegalovirus (CMV) infection and/or related diseases comprising contacting a test compound with at least one of the cellular kinases RICK, RIP, Nck-Interacting kinase, MKK3 and SRPK-2 (undefined) and detecting any change in kinase activity, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (1) detecting CMV infection and/or related diseases by detecting activity of any of the specified kinases in a patient sample, cells or cell lysates;
- (2) mono- or poly-clonal antibodies (Ab) that bind to any of the specified kinases;
- (3) preventing and/or treating CMV infection or related diseases, or for regulating production of CMV in an individual or cells, by administering an inhibitor or activator of any of the specified kinases;
- (4) oligonucleotides (ON) that bind to RNA or DNA encoding any of the specified kinases;
- (5) regulating expression of any of the specified kinases by administering to an individual, or cells, an inhibitor or activator of transcription of the relevant DNA or translation of the relevant RNA;
- (6) solid support for detecting CMV infection in an individual or cell comprising at least one immobilized ON able to detect activity of any of the specified kinases; and
- (7) solid support for screening (A) comprising one or more immobilized ON that encode any of the specified kinases or these kinases themselves.

ACTIVITY - Virucide. RICK was transiently overexpressed, as a fusion with a hemagglutinin (HA) tag, in human embryonic kidney 293 cells, then immunoprecipitated (anti-HA antibody and protein A-Sepharose). The beads were washed, then tested for kinase activity by incubation in a mixture containing gamma (33P)-adenosine triphosphate and various concentrations of 8-methyl-6-phenyl-2-(pyridin-4-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-on e (Aa). After 30 minutes at 30 deg. C, reaction was stopped and phosphorylation determined by electrophoresis and autoradiography. (Aa) has an inhibitory concentration (IC)50 for inhibition of RICK of 500 nM and for inhibition of CMV of 1.4 micro M.

MECHANISM OF ACTION - Modulation of cellular kinases that are specifically upregulated during CMV infection.

USE - (A) are used to treat and/or prevent CMV infections and related diseases. Oligonucleotides that can detect the specified kinases can also be used for diagnosis of infection.

ABSTRACTED-PUB-NO: EP 1201765A

EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/2